Wrapmanager Inc. Reduces Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Wrapmanager Inc. lowered its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 17.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,769 shares of the medical equipment provider’s stock after selling 566 shares during the quarter. Wrapmanager Inc.’s holdings in Lantheus were worth $304,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Moloney Securities Asset Management LLC purchased a new stake in Lantheus during the third quarter valued at approximately $1,066,000. Hancock Whitney Corp increased its stake in shares of Lantheus by 265.6% in the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after purchasing an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Lantheus in the 2nd quarter worth $290,000. Pitcairn Co. lifted its position in Lantheus by 117.0% during the first quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock valued at $521,000 after purchasing an additional 4,509 shares in the last quarter. Finally, Van ECK Associates Corp grew its holdings in Lantheus by 58.6% during the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after purchasing an additional 21,604 shares during the period. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 8th. JMP Securities decreased their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. Finally, B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Price Performance

NASDAQ:LNTH opened at $79.43 on Wednesday. The company has a market cap of $5.52 billion, a price-to-earnings ratio of 13.22 and a beta of 0.51. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock’s 50 day simple moving average is $104.07 and its two-hundred day simple moving average is $96.66.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.